临床试验搜索器

评论

*1-3 个肝脏病变可在进入研究前 6 周内通过 CT/MRI 或 PET/CT 检测到
*肝转移灶小于 5 厘米
*允许患有肝脏以外的疾病

联系方式

纳入标准

纳入标准

病理证实为非淋巴瘤肝转移或

病理确诊为非淋巴瘤癌症的已知患者出现与转移一致的新肝脏影像学病变

进入研究前 6 周内进行的 CT/MRI 或 PET/CT 检查发现 1-3 个可测量的肝脏病变

肝转移灶测量 6 个月

允许患肝脏以外的疾病

年龄 ≥ 18

ECOG 评分表 = 0-1

足够的骨髓功能，定义如下

* Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
* Platelets ≥ 60,000 cell/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
* Hemoglobin ≥ 8.0 g/dl based upon CBC/differential obtained within 4 weeks prior to registration on study (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)

肾功能正常（血清肌酐小于 2 毫克/分升），以登记参加研究前 4 周内获得的化学检查结果为依据

肝功能正常，即总胆红素为 2.0g/dL，血清肝酶水平小于正常值上限的 5 倍，以及 INR < 1.5 Previous liver resection or ablative therapy is permitted Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to radiation and started at least 14 days after completion of SBPT Women of childbearing potential and male participants must practice adequate contraception Patient must sign study specific informed consent prior to study entry Pretreatment evaluations required for eligibility include: * A complete history and general physical examination * For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to registration * INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to study entry

排除标准

排除标准：

曾患侵袭性恶性肿瘤（非黑色素瘤皮肤癌除外），但肝脏以外的原发性恶性肿瘤（非黑色素瘤皮肤癌除外）不在此列，除非无病时间超过 3 年

曾接受过放射治疗，导致辐射区域重叠

肝脏曾接受过放射治疗

可能影响生存的严重并发症

中枢神经系统转移

需要经常进行腹腔穿刺的张力性腹水

活动性肝感染

怀孕、哺乳期妇女或有生育能力的妇女，以及性生活活跃但不愿意/不能够使用医学上可接受的避孕方式的男性

胃肠道 2 厘米范围内的转移灶位置

-